title: IFN-gamma is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD).
abstract: Chronic granulomatous disease (CGD) is a genetic disorder characterized by recurrent bacterial and fungal infections and tissue granuloma formation. CGD phagocytes are unable to generate superoxide because of mutations in any of four proteins of the phagocyte NADPH oxidase. Prophylactic recombinant human interferon-gamma (IFN-gamma) has been shown to reduce the frequency and severity of infections in CGD patients, but its mechanism(s) remains undefined, and its benefit has been questioned. We investigated the prophylactic effect of IFN-gamma in the mouse model of the major autosomal recessive (p47(phox)) form of CGD. In a prospective, randomized, placebo-controlled study, we compared IFN-gamma, 20,000 U administered subcutaneously (s.c.) three times weekly, to placebo in 118 p47(phox-/-) mice. By 6 weeks of study, there were 3 infections in the IFN-gamma group compared with 13 infections in the placebo group (77% reduction in infections, p<0.01). By 18 months of study, there were 7 infections in the IFN-gamma group compared with 18 infections in the placebo group (39% reduction in infections, p<0.01). Two animals receiving IFN-gamma had seizures after 7 months in the study. No other toxicities were observed. Peripheral blood phagocytes from IFN-gamma treated p47(phox-/-) mice produced no superoxide, excluding restoration of the oxidative burst as a mechanism for the IFN-gamma effect. There were no differences in either peritoneal macrophage nitrate production or thioglycollate-induced peritoneal exudate between treatment groups. This animal model demonstrates a prophylactic benefit of IFN-gamma similar to that seen in humans and provides an opportunity to investigate the mechanism(s) of action for IFN-gamma in CGD.
authors.affiliation: The Laboratory of Host Defenses, NIAID, NIH, Bethesda, MD 20892, USA.
authors.forename: S H
authors.initials: SH
authors.lastname: Jackson
authors.forename: G F
authors.initials: GF
authors.lastname: Miller
authors.forename: B H
authors.initials: BH
authors.lastname: Segal
authors.forename: M
authors.initials: M
authors.lastname: Mardiney
authors.forename: J B
authors.initials: JB
authors.lastname: Domachowske
authors.forename: J I
authors.initials: JI
authors.lastname: Gallin
authors.forename: S M
authors.initials: SM
authors.lastname: Holland
mesh_terms: D000038:Abscess / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006105:Granulomatous Disease, Chronic / Q000201:enzymology / Q000235:genetics / Q000382:microbiology* / Q000473:pathology; D007371:Interferon-gamma / Q000627:therapeutic use*; D017737:Macrophages, Peritoneal / Q000201:enzymology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019255:NADPH Oxidases; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D010538:Peritonitis / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control; D010750:Phosphoproteins / Q000172:deficiency / Q000235:genetics; D011446:Prospective Studies; D011897:Random Allocation; D011994:Recombinant Proteins; D016897:Respiratory Burst / Q000235:genetics; D012874:Skin Diseases, Infectious / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D013864:Thioglycolates / Q000008:administration & dosage
chemical_list: D010750:Phosphoproteins; D011994:Recombinant Proteins; D013864:Thioglycolates; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1